This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca and Bristol-Myers Squibb.

Renal Cell Carcinoma

Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Stanford Health Center

40% of patients develop metastasis after primary surgical resection of localized renal cell carcinoma (RCC); this signifies an unmet need for the treatment of metastatic RCC. The mainstay of treatment has been antiangiogenic agents for previously untreated patients, and nivolumab has been shown to improve survival for patients who received prior antiangiogenic therapy. Details on the clinical trial upon which FDA approval for nivolumab was based on, as well as a case study illustrating how to appropriately manage immune-related dermatitis and arthritis are discussed in this video.



 
 

Download Slides


 
These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

JADPRO CE Logo APSHO Logo
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.